Service d'Hématologie Biologique, HCL, Hôpital Edouard Herriot, Lyon, France; EAM 4174 Hémostase, Inflammation et Sepsis, Université Claude Bernard Lyon 1, Lyon, France.
Haemophilia. 2014 Mar;20(2):e149-56. doi: 10.1111/hae.12346. Epub 2013 Dec 30.
Haemophilia A (HA) is an X-linked recessive bleeding disorder, caused by a wide variety of mutations in the factor VIII (F8) gene, leading to deficiency in the activity of coagulation FVIII. These mutations can affect all the F8 exons from the initiation codon to the termination codon, however, only few molecular changes in the promoter region of the F8 gene were reported so far. Here, we describe six nucleotide variations (c.-51G>A, c.-218T>C, c.-219C>T, c.-219delC, c.-221T>A and c.-664G>A) detected in the F8 promoter and their correlation with clinical phenotype of the patients. Potential role of these mutations in HA was also assessed. Causality was demonstrated with transient transfection experiments using luciferase reporter gene plasmids and computational analysis. Two molecular changes (c.-51G>A and c.-664G>A) did not seem to affect the promoter function of the F8 gene whereas c.-218T>C, c.-219C>T, c.-219delC, c.-221T>A mutations had an impact on the F8 promoter function and were responsible for HA. Furthermore, these mutations were associated with resistance to 1-deamino-8-D-argininevasopressin (desmopressin) therapy when they were causative. When molecular variation was detected in F8 promoter, we propose to use prediction software and to verify predictions by reporter gene analysis. If the mutation is causative, it will be probably associated with a lack of therapeutic response to desmopressin and this clinical implication should be considered by clinicians.
血友病 A (HA) 是一种 X 连锁隐性出血性疾病,由因子 VIII (F8) 基因的多种突变引起,导致凝血因子 VIII 活性缺乏。这些突变可以影响从起始密码子到终止密码子的所有 F8 外显子,但到目前为止,仅报道了 F8 基因启动子区域的少数分子变化。在这里,我们描述了在 F8 启动子中检测到的六个核苷酸变异(c.-51G>A、c.-218T>C、c.-219C>T、c.-219delC、c.-221T>A 和 c.-664G>A)及其与患者临床表型的相关性。还评估了这些突变在 HA 中的潜在作用。通过使用荧光素酶报告基因质粒的瞬时转染实验和计算分析证明了因果关系。两个分子变化(c.-51G>A 和 c.-664G>A)似乎不会影响 F8 基因的启动子功能,而 c.-218T>C、c.-219C>T、c.-219delC、c.-221T>A 突变对 F8 启动子功能有影响,是 HA 的原因。此外,当这些突变是致病突变时,它们与 1-脒基-8-D-精氨酸加压素(去氨加压素)治疗的耐药性相关。当在 F8 启动子中检测到分子变异时,我们建议使用预测软件并通过报告基因分析验证预测。如果突变是致病的,它可能与去氨加压素治疗反应缺乏相关,临床医生应考虑这一临床意义。